ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair deficient (MMR-D) gene or microsatellite instability high (MSI-H) gene. The researchers will see how doctors and their patients use the results of ctDNA testing after 1 year of standard chemotherapy and immune checkpoint inhibitor (ICI) treatment to decide whether to continue maintenance ICI treatment past 1 year. The researchers will also look at the health outcomes of people in this study (for example, whether they are cancer free at the end of their participation in the study).

NCT Number	NCT07270666
Lead Sponsor	Memorial Sloan Kettering Cancer Center
Conditions	Endometrial Cancer
Enrollment	30 participants
Start Date	2025-11-25
Primary Completion	2027-11 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-13